Frontlight ResearchEarly access
CompletedNo phase
MASTERMIND-Pneumonia Study (Also Known as Pneumonia Direct Pilot)
Key facts
- Who runs it
- Duke University
- Where
- Detroit, Pittsburgh, Royal Oak, and St Louis, United StatesSee the 4 sites
- Trial code
- Status
- Completed
- People taking part
- 173 people enrolled
- Started
- 12 Apr 2024
- Ended
- 3 Jul 2025
- Type of study
- Observational
- Treatments tested
- Pathogen and Host Directed testing
- Record updated
- 27 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Are ≥18 years old
- Are newly intubated for less than 48 hours and for reasons other than suspected bacterial pneumonia or suspected acute bacterial infection
- Are expected to require intubation for at least 48 hours, per the discretion of the treating clinician
- Are able to provide protocol-accepted consent (legally authorized representative [LAR] is acceptable)
- Are expected to live long enough to receive a VAP diagnosis, at the discretion of the treating clinician
- Are able to provide study-required biological samples
Who cannot take part
- Received a lung transplant
- Are receiving comfort care
- Are receiving antibiotic treatment for suspected or proven active acute bacterial infection (eg, pneumonia, tracheobronchitis, sepsis)
- Were previously enrolled in this trial
- Are currently participating in an interventional drug or device study
- Have known active lung cancer or metastatic disease to a lung
- Have a witnessed or suspected aspiration event prompting the need for current, new intubation
- Have cystic fibrosis
- Have a current or within-the-last-30-days diagnosis of active bacterial pneumonia
- Require long-term ventilator support
- Have a tracheostomy tube in place
Where in United States
- Henry Ford HospitalDetroit, United States
- University of Pittsburgh Medical CenterPittsburgh, United States
- Corewell (William Beaumont)Royal Oak, United States
- Washington University School of Medicine in St. LouisSt Louis, United States
About the trial
What the trial wants to find out
The MASTERMIND-Pneumonia Study (also known as Pneumonia Direct Pilot Study) is designed to assess whether combining molecular diagnostics for bacteria and AMR markers with host-response profiling improves agreement and predictive value for the diagnosis of VAP versus an adjudicated clinical reference standard. The feasibility design is intended to inform future interventional studies that will investigate the clinical impact of combined pathogen- and host-directed testing approaches.
The group in the trial
- Standard of Care
There are no interventions in this study. Standard of care activities will be captured in the eCRF and samples will be collected and tested. Results will not be returned to the sites or participants.
Treatment: Pathogen and Host Directed testing
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pneumonia Direct Pilot
- Record updated
- 27 April 2026